Crossmark

Conventional dose versus dose escalated radiotherapy including high-dose-rate brachytherapy boost for patients with Gleason score 9–10 clinical localized prostate cancer

Crossref DOI link: https://doi.org/10.1038/s41598-021-04233-4

Published Online: 2022-01-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yamazaki, Hideya

Suzuki, Gen

Aibe, Norihiro

Shimizu, Daisuke

Kimoto, Takuya

Masui, Koji

Yoshida, Ken

Nakamura, Satoaki

Okabe, Haruumi
License Information

Text and Data Mining valid from 2022-01-07

Version of Record valid from 2022-01-07
More Information

Article History

Received: 15 June 2021

Accepted: 17 December 2021

First Online: 7 January 2022

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below